Sol-Gel Technologies (SLGL) Return on Capital Employed (2018 - 2026)
Sol-Gel Technologies (SLGL) reported Return on Capital Employed of 14.2% for Q1 2026, up 19.0% year-over-year from 11.94% in Q1 2025, and down 65.05% quarter-over-quarter from 40.64% in Q4 2025.
Sol-Gel Technologies (SLGL) Return on Capital Employed (2018 - 2026) Analysis & Trends
Sol-Gel Technologies (SLGL) has 9 years of Return on Capital Employed data on file, last reported at 14.2% in Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 14.2%, up 19.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 14.2% (up 19.0% YoY), and the FY2025 annual result was 28.22%, up 583.0% from the prior year.
- Return on Capital Employed eased to 14.2% in Q1 2026 per SLGL's latest filing, from 40.64% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 50.03% in Q1 2022 and troughed at 30.85% in Q1 2024.
- A 5-year average of 11.05% and a median of 5.84% in 2024 frame the typical range for Return on Capital Employed.
- On a YoY basis, Return on Capital Employed climbed as much as 5711 bps in 2022 and fell as far as 6324 bps in 2022.
- A 5-year view of Return on Capital Employed shows it stood at 7.49% in 2022, then tumbled by 123 bps to 16.67% in 2023, then soared by 125 bps to 4.13% in 2024, then soared by 884 bps to 40.64% in 2025, then tumbled by 65 bps to 14.2% in 2026.
- Business Quant data shows SLGL's Return on Capital Employed at 14.2% in Q1 2026, 40.64% in Q4 2025, and 25.69% in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Sol-Gel Technologies | 207.80 Mn | 197.67 Mn | - | 14.20% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.20% |
| Dec 31, 2025 | 40.64% |
| Sep 30, 2025 | 25.69% |
| Jun 30, 2025 | 47.37% |
| Mar 31, 2025 | 14.01% |
| Dec 31, 2024 | 4.13% |
| Sep 30, 2024 | 5.84% |
| Jun 30, 2024 | -9.45% |
| Mar 31, 2024 | -30.85% |
| Dec 31, 2023 | -16.67% |
| Sep 30, 2023 | -16.63% |
| Jun 30, 2023 | -11.41% |
| Mar 31, 2023 | 3.86% |
| Dec 31, 2022 | -7.49% |
| Sep 30, 2022 | 33.14% |
| Jun 30, 2022 | 41.39% |
| Mar 31, 2022 | 50.03% |
| Dec 31, 2021 | 55.76% |
| Sep 30, 2021 | 17.10% |
| Jun 30, 2021 | -7.11% |